A world-class chemical franchise with 20%+ EBITDA margins—trapped in a ‘good business, bad balance sheet’ deleveraging race against the cycle.
Overview
Celanese (CE) is a global chemicals and specialty materials producer with two complementary segments: Acetyl Chain (integrated acetyls and derivatives; global cost leader in acetic acid/VAM) and Engineered Materials (advanced polymers, now larger after acquiring DuPont’s Mobility & Materials). In FY2025, net sales fell to $9.54B (-7% YoY) amid macro headwinds, destocking, and deflationary commodity pricing. The company reported a GAAP loss (EPS -$10.44) driven largely by noncash impairments tied to the M&M acquisition (notably ~$1.1B goodwill and $346M trade name). Operationally, the franchise remained cash-generative: adjusted EPS was $3.98, free cash flow reached $773M (+50%+ YoY), and both segments defended >20% operating EBITDA margins through the trough. However, Celanese is in a precarious phase due to a heavily leveraged balance sheet (~$12.6B debt) from debt-funded M&A at the prior cycle peak. Strategy has shifted decisively from expansion to capital preservation and rapid deleveraging: a 95% dividend cut to $0.03/quarter, non-core asset sales (Micromax for $492M), permanent capacity closures (Lanaken), broad cost and working-capital programs, and negotiated covenant relief. The equity thesis is now primarily a leveraged bet on sustained free cash flow being sufficient to pay down debt before the macro cycle or covenants force more drastic actions.